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Abstract A4 - Table 1 
Placebo (N=104) Acetaminophen (N=108) Glucosamine sulfate (N=106) 
Baseline 6 months Baseline 6 months Baseline 6 months 
Lequesne (points)a 10.8 (2.6) -1.9 (-2.6 to -1.2) 11.1 (2.7) -2.7 (-3.3 to -2.1) 11.0 (3.1) -3.1" (-3.8 to -2.3) 
WOMAC (points)a 37.9 (14.3) -8.2 (-11.3 to -5.1) 40.4 (14.8) -12.3 (-14.9 to -9.7) 38.3 (15.2) -12.91 (-15.6 to -10.1) 
OARSI-A responders (%) - 21.2% 33.3%~: 39.6%§ 
a Mean absolute (SD) at baseline and change (95%CI) at 6 months. P vs placebo: *0.032 [difference = -1.2 (-2.3 to -0.8)]; 10.039 [difference = -4.7 (-9.1 to -0.2)]; 
~:0.047; §0.007 
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Purpose: To define the role of Toll-like receptor(TLR) mediated 
signaling in the catabolic pathway in cultured human articular 
chondrocytes. 
Methods: Cartilage samples were obtained from OA and femur 
neck fracture patients and chondrocytes were cultured in both 
monolayer and explant. For evaluation of the expression of TLR 
in cartilage specimens, immunohistochemistry for TLR-2 and 4 
were performed. Regulation of TLR expression in cultured chon- 
drocytes was observed by RT-PCR. For stimulation of TLR2 and 
4, chondrocytes were treated with Staphylococcus aureus pep- 
tidoglycan(PGN) and liposaccharides (LPS), as TLR2 and 4 lig- 
ands, respectively. Production of MMP-1,3, 13 and prostaglandin 
(PG) E2 was evaluated by ELISA assay. Production of nitric ox- 
ide (NO) was analyzed by Griess reaction. Phosphorylation of 
JNK and NF-kB activation were observed with Western blot and 
electrophoretic mobility shift assay, respectively. 
Results: Expression of TLR 2, and 4 was upregulated in lesion 
area of OA cartilage. Treatment with interleukin-1, tumor necro- 
sis factor-alpha, PGN and LPS all significantly upregulated both 
TLR2 and TLR4 expression in cultured chondrocytes. Production 
of MMP-1, 3, and 13, NO and PGE2 significantly increased af- 
ter treating chondrocytes with either PGN or LPS, which was 
inhibited by anti-TLR antibodies. Treatment with PGN and LPS 
led to phosphorylation of JNK and activation of NF-kB. Pretreat- 
ment of chondrocytes with JNK inhibitor SP600125 and NF-kB 
inhibitor, MG132 led to significant downregulation of all catabolic 
responses mediated by TLR ligands. 
Conclusion: TLR ligands function as stimulants of chondrocyte 
catabolism. TLR mediated signaling may play an important role in 
the cartilage degradation in rheumatoid and osteoarthritis. Eluci- 
dation of endogenous TLR ligands working as a catabolic stimuli 
on chondorcytes is the subject of further research. 
A4 
EFFECTS OF GLUCOSAMINE SULFATE ON 6-MONTH 
CONTROL OF KNEE OSTEOARTHRITIS SYMPTOMS VS 
PLACEBO AND ACETAMINOPHEN: RESULTS FROM THE 
GLUCOSAMINE UNUM IN DIE EFFICACY (GUIDE)TRIAL 
G Herrero-Beaumont 1 , JA Rom~.n 2, MC Trabado 3, FJ Blanco 4, 
P Benito 5, E Martin-Mola 6, J Paulino 7, JL Marenco 8, A Porto 9, 
A Laffon 1°, D Araejo 11 , M Figueroa 12, J Branco 13 
1Rheumatology, Fund J Diaz, Madrid, Spain; 2H Peset, Valencia; 
3H Clinic, Barcelona; 4CH Juan Canalejo, A Coruha; 5H del Mar, 
Barcelona; 6H U La Paz, Madrid; 7C H C R, Ciudad Real; 8H 
N.S. de Valme, Sevilla 9H U, Coimbra; l°H Princesa, Madrid; 11H 
C. Bertandos, Ponte de Lima; 12H Donostia, San Sebastian; 13H 
E. Moniz, Lisboa, Portugal 
Aim of Study: Two multicenter, randomised, placebo-controlled, 
double-blind trials lately investigated the efficacy of oral glu- 
cosamine in knee osteoarthritis (OA), using a symptomatic med- 
ication as reference: GAIT performed by the NIH in the US with 
nutraceutical glucosamine hydrochloride 500 mg t.i.d, vs cele- 
coxib, and GUIDE performed in Europe with the prescription 
glucosamine sulfate (GS) 1500 mg once-a-day (u.i.d.) vs ac- 
etaminophen, i.e. the preferred symptomatic medication in OA 
practice guidelines. We report the results of GUIDE. 
Methods: 318 patients (88% women) with knee OA (ACR crite- 
ria) were randomised to double-dummy oral GS soluble powder 
1500 mg u.i.d., or acetaminophen 1000 mg tablets t.i.d. (3 g/day, 
as recommended in Europe), or placebo for 6 months. The res- 
cue medication consisted of standardised use of ibuprofen 400 
mg tablets (daily diary recording). The primary efficacy parame- 
ter was the ITT 6-month change in the Lequesne index, using the 
LOCF approach for patients not completing the study according 
to the protocol (34 on placebo, 28 in each the acetaminophen 
and GS groups, without differences in drop-out reasons). Sec- 
ondary efficacy parameters included the WOMAC index and the 
OARSI-A responder criteria. Analysis on the indexes was per- 
formed by GLM-ANOVA, with Dunnett's pairwise comparisons vs 
placebo. The proportions of responders and patients using the 
rescue medication were compared by the chi-square test. 
Results: The groups were comparable for demographics and 
baseline disease characteristics. GS efficacy vs placebo was sig- 
nificant on all parameters (Table 1). Acetaminophen had more 
responders than placebo, but it failed to reach a significant differ- 
ence on the Lequesne (p=0.18) and WOMAC (p=0.077) indexes. 
More patients on placebo used the rescue medication (p=0.027 
and 0.045 vs GS and acetaminophen, respectively). There were 
no differences among groups in safety. 
Conclusions: Glucosamine sulfate at the oral once-daily dose of 
1500 mg might be the preferred symptomatic medication in knee 
OA. 
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Aim of Study: Subchondral trabecular bone loss is character- 
istic of progressive knee OA (Messent et al, Osteoarthritis Cart 
2005;13:463-70). This study determined whether risedronate, a 
bisphosphonate, slowed this loss of bone within the proximal tibia 
of patients with medial compartment disease. 
Methods: 100 patients were randomly selected from each treat- 
ment group (each N~300) comprising placebo, and risedronate 
5mg qd, 15mg qd and 50mg qwk from a large double blind, mul- 
ticenter, placebo-controlled 2-year investigation of patients with 
knee OA, joint space width (JSW) between 2-4 mm, at least one 
osteophyte present and knee pain most days of 1 month in last 
